Caprion Proteomics, Inc. Completes Recapitalization

Montreal, Quebec - Friday, July 20, 2012 – Chicago Growth Partners has completed a recapitalization of Caprion Proteomics, Inc., a leading provider of integrated proteomic biomarker and target identification solutions and advanced immune monitoring services to the world’s largest and most successful pharmaceutical and biotechnology companies as well as government research organizations. Prior to this acquisition, Caprion Proteomics was a portfolio company of Great Point Partners, LLC.

Caprion’s key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development. The Company’s multi-disciplinary team which includes experts in biology, chemistry, and bioinformatics has developed a highly integrated, industrialized approach that produces unrivaled information used by pharmaceutical and biotechnology clients to manage their therapeutic development pipelines. Caprion’s proprietary proteomics technology, CellCarta®, is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large sets of biological samples. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has over a decade of experience providing large-scale proteomics biomarker and drug target discovery and validation services for over 50 major clients in the pharmaceutical, biotech and public sectors.

Martin LeBlanc, President and CEO of Caprion commented, “We are very pleased with this transaction and to begin this exciting new partnership with Chicago Growth Partners. CGP’s solid track record of successfully supporting management teams and providing strategic leadership will help position Caprion to sustain the rapid growth achieved over the past four years as we continue to capitalize on the growing demand for integrated proteomic and advanced immune monitoring services in the development of novel therapeutics and diagnostics.”

Adam Dolder, Managing Director of Great Point Partners and former Chairman of Caprion, stated “We could not be more thrilled with the successful outcome of our investment in Caprion. This transaction is a testament to the vision that we shared with Martin and a compliment to his excellent leadership in bringing that vision to reality. Caprion is a truly differentiated company that capitalizes on the major needs of its pharmaceutical and biotech clients and the value achieved in the transaction proves that point.”

Neal McCarthy, Managing Director of Fairmount Partners, who assisted Caprion and Great Point Partners in this transaction commented, “With the support and resources of Chicago Growth Partners, Caprion is poised to take advantage of its critical mass and make significant contributions within the evolving field of biomarkers.”

About Fairmount Partners

Fairmount Partners is one of the largest investment banking groups in the Mid-Atlantic region. The firm specializes in advising middle-market growth companies with mergers and acquisitions, capital raising and strategic advice. Fairmount’s key focus areas include: IT and Business Services, Healthcare, Industrial/Consumer and Software/Technology. Fairmount has completed transactions throughout North and South America, Europe and Asia. For more information, visit: www.fairmountpartners.com.

Principals of Fairmount Partners acted as advisors to Caprion Proteomics, Inc. in this transaction.

Contact

Neal McCarthy

Managing Director, Fairmount Partners

neal.mccarthy@fairmountpartners.com